ALKS

Rating neutralAI Memo

Alkermes

As of 2026-05-29/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Q1 results confirm post-Avadel scale-up • 2026-05-05

Expected move: +6%

Biggest risk

The bear case is execution and capital structure: the company used about $775M of cash and added $1.525B of term loans for Avadel, so balance-sheet risk is higher; LUMRYZ for idiopathic hypersomnia cannot be marketed or supported before March 1, 2028 under the settlement/license, and the phase 3 win still needs full disclosure, filing, FDA review, and payer uptake.

Invalidation

Break below $33 or thesis failure.

What would change my mind?

The bull case is that Alkermes is emerging as a scaled neuroscience platform: Q1 revenue was $392.9M, adjusted EBITDA was $80.3M, LUMRYZ added $39.5M in a partial quarter, and REVITALYZ was positive with an sNDA path by year-end 2026. If LUMRYZ ramps as guided, the market may keep rewarding the sleep-franchise buildout and improved reported profitability.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-29

Base target

$44

p=50%

Bull target

$52

p=25%

Bear target

$33

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

May 20 governance 8-K is a minor watch item
REVITALYZ readout expands LUMRYZ optionality
LUMRYZ commercialization and Avadel integration

BearKey bullets

Avadel integration and leverage are the biggest near-term financial risks: cash, cash equivalents, restricted cash and investments fell to $538.2M at March 31, 2026 while term loans totaled $1.525B.
CNS depression, abuse/misuse, and respiratory-depression warnings remain material for LUMRYZ, and the REMS-restricted distribution model adds operational friction.
LUMRYZ for idiopathic hypersomnia is contractually constrained: Alkermes may not market, offer for sale, promote, or provide patient support before March 1, 2028 even if FDA approval comes earlier.

WatchKey bullets

Q1 results confirm post-Avadel scale-up

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $44 (p=50%)

Bull/Bear spread: +26% / -20%

Vs latest close: Bull +26% · Base +6% · Bear -20%

Scenario probabilities

Bull Target: $52 (p=25%)Base Target: $44 (p=50%)Bear Target: $33 (p=25%)

Commentary

Primary-source evidence is strong and the recent news flow is constructive, but this remains a monitoring-style biopharma setup rather than a high-conviction growth call. The positive phase 3 sleep readout improves the long-term thesis, while leverage, REMS and licensing constraints, and the need for filing/review keep near-term visibility limited. No fresh analyst revision data were available in the packet, so confidence stays moderate.

As of 2026-05-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

May 20 governance 8-K is a minor watch item
REVITALYZ readout expands LUMRYZ optionality
LUMRYZ commercialization and Avadel integration

Scenarios

Bull Target (Scenario probability)

$52 / p=25% prob

Base Target (Scenario probability)

$44 / p=50% prob

Bear Target (Scenario probability)

$33 / p=25% prob

Price $41 as of 2026-06-02

Nearest Scenario: Base (∆ 6%)

Targets vs latest close: Bull +26% · Base +6% · Bear -20%

Sentiment & Exposure

News Sentiment (30d)

0.67

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-05
Q1 results confirm post-Avadel scale-up
Alkermes reported Q1 2026 revenue of $392.9M, GAAP net loss of $66.5M, and adjusted EBITDA of $80.3M; LUMRYZ contributed $39.5M in its first partial quarter post-close, and management kept full-year 2026 revenue guidance unchanged while improving GAAP net loss and EBITDA expectations after Avadel purchase accounting [#IR-2026-05-05].
Prob 70.00% • Move 5.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

May 20 governance 8-K is a minor watch item
2026-05-20
The May 20 8-K disclosed a director/officer departure and compensatory-arrangements items; this is worth monitoring for governance context, but it does not appear to change the core operating thesis [#8-K-2026-05-20].
Prob 30% • Move 2% • Priced-in 15%

Long-term Catalysts

Months to a year

REVITALYZ readout expands LUMRYZ optionality
2026-12-31
The company announced positive topline REVITALYZ phase 3 results in idiopathic hypersomnia, with LUMRYZ meeting the primary endpoint and key secondary endpoints; Alkermes said it plans to present detailed data and file an sNDA with the FDA by the end of 2026, extending the sleep-franchise catalyst path [#IR-2026-05-12].
Prob 82% • Move 9% • Priced-in 45%
LUMRYZ commercialization and Avadel integration
2026-12-31
Management's 2026 framework still calls for LUMRYZ net sales of $315M-$335M and total revenues of $1.73B-$1.84B; the key long-duration question is whether Alkermes can convert the acquired sleep asset into durable growth while absorbing higher acquisition-related expenses and keeping the balance sheet under control [#IR-2026-05-05].
Prob 70% • Move 12% • Priced-in 60%

Risks

Avadel integration and leverage are the biggest near-term financial risks: cash, cash equivalents, restricted cash and investments fell to $538.2M at March 31, 2026 while term loans totaled $1.525B.
CNS depression, abuse/misuse, and respiratory-depression warnings remain material for LUMRYZ, and the REMS-restricted distribution model adds operational friction.
LUMRYZ for idiopathic hypersomnia is contractually constrained: Alkermes may not market, offer for sale, promote, or provide patient support before March 1, 2028 even if FDA approval comes earlier.
The REVITALYZ result is positive but still requires detailed data presentation, sNDA submission, and FDA review before it becomes incremental cash flow.

Peers

Symbol	Summary
ACAD	Closest CNS commercial peer for neuropsychiatry execution and specialty-pharma operating discipline; useful for read-through on promotional efficiency and payer traction.
INDV	Relevant addiction/CNS commercialization peer with a similar specialty-pharma go-to-market profile, though less directly exposed to the sleep franchise.
RYTM	Loose same-sector growth comp with neurology/sleep-adjacent exposure; helpful as a valuation cross-check, but not a clean operating peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-29

AI Stock Memo: ALKS - Alkermes - RankAlpha